SAMSARA BIOCAPITAL, LLC
An institutional investment manager in PALO ALTO, CA. Its Form 13F for the quarter ended Jun 30, 2026, filed Aug 14, 2026. SEC CIK 1744967.
- Reported value$1.22bn
- Positions24
Holdings: 24 positions
The filing on sec.govAs filed, largest first. Reported value is what the manager stated for each position at the quarter end, in US dollars; it is filing data, not a price. Weight is the position's share of the total reported value. Changes compare with the 13F for the quarter ended 2026-03-31.
| Issuer | Class | CUSIP | Reported value$m | Weight | Shares | Put or call | Change on the quarter before |
|---|---|---|---|---|---|---|---|
| Scholar Rock HLDG CorpSRRK | COM | 80706P103 | 379 | 31.2% | 6,897,652 | Unchanged | |
| Alumis IncALMS | COM | 022307102 | 179 | 14.7% | 6,345,219 | Unchanged | |
| Mineralys Therapeutics IncMLYS | COM | 603170101 | 158 | 13.0% | 5,871,018 | Unchanged | |
| Septerna IncSEPN | COM | 81734D104 | 105 | 8.7% | 3,149,128 | Unchanged | |
| Alamar Biosciences IncALMR | COMMON STOCK | 010911105 | 67.2 | 5.5% | 2,480,310 | New+2,480,310 | |
| Neurogene IncNGNE | COM | 64135M105 | 54.0 | 4.4% | 1,717,127 | Unchanged | |
| Kalaris Therapeutics IncKLRS | COM | 482929106 | 52.4 | 4.3% | 12,881,175 | Reduced−66,906 | |
| Spyglass Pharma IncSGP | COM SHS | 85220G109 | 47.0 | 3.9% | 2,109,953 | Unchanged | |
| Sutro Biopharma IncSTRO | COM SHS | 869367201 | 35.3 | 2.9% | 1,062,872 | Unchanged | |
| Inventiva SAIVA | ADS | 46124U107 | 23.9 | 2.0% | 6,314,805 | Added+1,120,000 | |
| Jade Biosciences IncJBIO | COM NEW | 008064206 | 16.4 | 1.3% | 736,237 | Reduced−232,561 | |
| Parabilis Medicines IncPBLS | COM | 698955101 | 15.2 | 1.3% | 556,044 | New+556,044 | |
| VTV Therapeutics IncVTVT | CL A NEW | 918385204 | 11.2 | 0.9% | 298,496 | Unchanged | |
| Aquestive Therapeutics IncAQST | COM | 03843E104 | 10.4 | 0.9% | 2,500,000 | Unchanged | |
| Nkarta IncNKTX | COM | 65487U108 | 9.9 | 0.8% | 3,507,666 | Unchanged | |
| Artiva Biotherapeutics IncARTV | COM | 04317A107 | 9.3 | 0.8% | 954,861 | New+954,861 | |
| Rani Therapeutics Holdings IncRANI | COM CL A | 753018100 | 7.9 | 0.6% | 10,369,159 | Added+1,869,159 | |
| Agomab Therapeutics NVAGMB | SPONSORED ADS | 00860C102 | 7.8 | 0.6% | 600,000 | Unchanged | |
| Abivax SAABVX | SPONSORED ADS | 00370M103 | 7.3 | 0.6% | 55,095 | Reduced−1,486 | |
| X4 Pharmaceuticals IncXFOR | COM NEW | 98420X202 | 6.5 | 0.5% | 1,395,587 | Reduced−436,979 | |
| Eloxx Pharmaceuticals IncELOX | COM NEW | 29014R301 | 5.6 | 0.5% | 400,000 | New+400,000 | |
| Coherus Oncology IncCHRS | COM | 19249H103 | 4.8 | 0.4% | 3,428,571 | Unchanged | |
| Upstream Bio IncUPB | COM | 91678A107 | 2.4 | 0.2% | 353,717 | Reduced−382,330 | |
| Gossamer Bio Inc | COM | 38341P102 | 1.2 | <0.1% | 7,222,559 | Unchanged |
Sold out: 2 positions
Held at the end of the quarter before and not reported this quarter.
| Issuer | Class | CUSIP | Reported value$ | Weight | Shares | Put or call | Change on the quarter before |
|---|---|---|---|---|---|---|---|
| Arcellx Inc | COMMON STOCK | 03940C100 | 0.0 | 0.0% | 0 | Sold out−60,873 | |
| Palvella Therapeutics Inc NePVLA | COM | 697947109 | 0.0 | 0.0% | 0 | Sold out−38,432 |
Source: SEC EDGAR, Form 13F-HR, accession 0001744967-26-000010 (on sec.gov). Last ingested by Listed: Oct 22, 2026, 05:26 ET. Listed shows no prices and gives no investment advice.